LONDON, May 17, 2016 /PRNewswire/ --
- Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells
- Biobanks - How to Discover Trends, R&D and Sales Forecasts From 2016, Helping Your Influence
Are you interested in the future of medical biobanking? If so, you can now gain technological and commercial predictions from 2016. That way you stay ahead for data, benefiting your authority. There explore trends in research and development, results, opportunities and revenue forecasts.
That new study by visiongain shows you what is possible for biobanking and associated technology for human healthcare. Avoid missing out. Instead find sales potentials for that biomedical industry and market, discovering expected trends, progress and financial gains.
Biobank services and technology exert great influence on drug discovery and development. That importance increases from 2016. See what the future holds.
Potential of those biorepository technologies and storage facilities
In medical research those biostorage systems form an important resource. They support fields including genomics and personalised medicine, letting companies store and use samples.
Our report's purpose is showing you the commercial potential in storing human biological samples for use in research and therapies, including conserving stem cells.
Please read on to explore those technologies and services for human medicine, finding what influences that market and seeing predicted revenue.
Forecasts and other information showing lucrative possibilities for biorepositories
Our study gives sales predictions to 2026 at overall world, submarket and national level. You also get sample unit predictions. For biosample and biospecimen storage, especially for pharmaceutical R&D, you investigate where applications, needs, demand and money lie.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Why struggle to find information or miss data you need on medical biopreservation? Besides revenue forecasting, our new analysis shows you results, growth rates and market shares.
There you explore those technologies for medical R&D - especially applications suiting drug companies. Our new report gives you 72 tables, 74 charts and three interviews with authorities in that field. Discover, from 2016, the potential of biobanks.
Forecasting of that world market and its segments - you find commercial prospects
See in our report overall world revenue to 2026, with discussions, for storing human cell, tissue and fluid samples.
That way you can help your research, analyses and decisions on storage of human biological samples (HBS). As someone with authority, benefit your reputation for technological and commercial insight.
In particular find individual revenue predictions to 2026 for nine submarkets at world level:
• Biobanking for research
• Biobanking for therapeutic uses.
There you find biobanking revenue forecasting to 2026 by research application:
• Human tissues - also with sub-forecasts for public sector and commercial uses
• Stem cells
• Other biological sample banking applications - inc. DNA and body fluids.
And our analysis predicts stem cell banking revenues to 2026 for therapeutic uses:
• Umbilical cord stem cell banking
• Adult stem cell banking.
You also get forecasts to 2026 for the number of samples banked for research and therapeutic applications.
In our study you assess outlooks for sales expansion, hearing where you could gain. That work explores competition and demand, showing technological and commercial possibilities.
So hear what is happening. You also investigate geographical revenue potentials.
Biostorage needs in leading national markets - what outlooks for demand, sales and capacity?
In developed and developing countries, opportunities for companies providing biorepository facilities, products, services, consumables and technology will expand from 2016.
Our analyses show you individual revenue forecasts to 2026 for 12 leading national biobanking markets:
• The US
• Japan
• Germany, France, the UK, Italy, Spain and the Netherlands
• Brazil, Russia, India and China.
There discover countries with highest sales, demand and potential expansion of usage and revenues. That way you investigate progress, needs, opportunities and competitors. And you see the gains possible, finding how you could expand your business.
Also what events, challenges and advances in technology affect biorepositories?
Forces influencing suppliers and users of those biomedical resources and libraries
Our new study explores issues, events and contributions affecting that industry and market from 2016, including these influences:
• Guidelines, research and medical ethics, standards (e.g. GLP), legislation, regulations and governmental funding for that biopreservation, inc. HIPAA amendments
• Systems for cryopreservation, biobank networks and biobanking infrastructure
• Facilities, freezers, operations software, consumables and services
• Biobanking in research, drug discovery and development, inc. biomarkers and personalised medicine
• Uses in therapeutics, clinical trials and genome-wide association studies (GWAS).
And you explore these forces, among others:
• Numbers and geographical distribution of biobanks
• Umbilical cord blood banking and induced pluripotent stem cells (iPSCs)
• RFID, tagging technology and laboratory information management systems (LIMS)
• Technologies and services aiding genetic epidemiology studies and understanding of disease pathways
• Automated liquid handling systems, and automation in DNA isolation
• Biobanking services - sample storage, tracking, management and transport of human biological samples.
That way you find what stimulates and restrains organisations performing and helping that biosample preservation, affecting their results and those of biobank clients.
Technologies and applications - top organisations and 2020 market value
What future sales results are possible? Our study predicts that the world biobanking market will generate $27.5bn in 2020. Rising demand for biobanked samples for use by pharmaceutical companies in preclinical research most stimulates biobanking revenues.
Our analysis shows activities of biobanks, including these organisations:
• Stemgent
• Biopta
• BioServe
• Coriell Institute for Medical Research
• Cord Blood America
• Cryo-Cell International.
And other companies, including these:
• China Cord Blood Corp
• LifebankUSA
• ViaCord
• Cord Blood Registry
• Biogenea Pharmaceuticals
• StemLife
• Caladrius Biosciences.
That way you assess competitors and developments. Our analysis includes interviews with Fidelis Research, Bulgaria, 3C-R, France, and the UK ME/CFS Biobank Project. So avoid missing out in knowledge. See what other authorities say and do, helping your work.
Five ways Biobanking Market Forecasts 2016-2026 helps your work
In these five main ways, our new investigation helps you get recognition for insight, saving time and benefiting your authority:
• Revenues for biobanking, to 2026, at world level and for 9 submarkets - explore prospects for design, production, sales, marketing, demand and spending
• Forecasts, to 2026, for 12 countries in the Americas, Europe and Asia - assess developed and developing national markets for demand and predicted revenues
• Prospects for established organisations, rising companies and new entrants - examine service and product portfolios, results, strategies and outlooks for success
• Analysis of what stimulates and restrains that industry's participants - investigate challenges, strengths and competition affecting organisations' results
• Interviews with organisations - discover what authorities in that field say and do, helping you stay ahead in knowledge to help your work.
That report, by visiongain's UK-based analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. You get data leading companies depend on.
Information there found nowhere else, helping your searches, analyses and planning
An off-the-shelf report cannot answer every question, though our work explains that industry's structures, outlooks and potentials.
Our analyses give independent data. There you get competitive intelligence found only in that study, finding where progress, money and opportunities lie. See what the future holds.
With that research and analysis you are less likely to fall behind in knowledge or miss opportunity. There see how you could save time and effort. And benefit your plans, decisions and presentations, helping you gain advantages and recognition.
Trying our study now lets you discover biobanking opportunities and predictions
Stay ahead in data. Our new investigation is for everyone analysing medical biotechnology and pharmaceutical R&D. For storing biological samples you see trends, opportunities and revenue predictions. So avoid missing out - please get our new report here now.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1635/Biobanking-Market-Forecasts-2016-2026
Company mentioned
3C-R
100,000 Genomes Project
Abbott Laboratories
Accelrys
AdeptBio
Adnexus Therapeutics
Advanced Innovative Medicine
AIS
AKH Biobank
AllCells
Allied Minds
AlloSource
AMAG Pharmaceuticals
American Association of Tissue Banks
American CryoStem
American Type Culture Collection (ATCC)
Amgen
Analytical Biological Services
ARUP Laboratories
ASPREE Healthy Ageing Biobank
AssureImmune
Asterand Biosciences
AstraZeneca
Aurora Biomed
Australian Biospecimen Network (ABN)
Autoscribe Informatics
AuxoCell Laboratories
AXM Shenyang
Bangalore Brain Bank
Barts Gynae Tissue Bank
Bavarian Red Cross (BRK)
Bayer
BBMRI
Beckman Coulter
Benelux
BINDER
Biobank Ireland Trust
BioCision
Biocordcell Argentina
BioEden
BioFortis
Biogen Idec
Biogenea
Biogenea Pharmaceuticals
BioLife Solutions
Biomatrica
Biomedical Research Council (BMRC)
Biopta
BioreclamationIVT
BioRep
BioRepository Resources
Bioserve Biotechnologies
BioServe Biotechnologies India
BioStorage Technologies
Biovault Technical
BIOVIA
Bluechiip Ltd.
BrainNet Europe
Bristol-Myers Squibb
British Birth Cohort
Brooks
Brooks Life Science Systems
Caladrius Biosciences
Cambridge Biomedical Research Centre
Cambridge Biosciences
Canadian Partnership for Tomorrow
Cancer Genetics Inc
Cancer Genetics India
Cancer Human Biobank (caHUB)
CCLG Tissue Bank
Celgene Cellular Therapeutics
Cells4Life
Celltex Therapeutics
Cellular Dynamics
Center for iPS Cell Research and Applications (CiRA)
Centro Nazionale per le Risorse Biologiche (CNRB)
Cesca Therapeutics
Chernobyl Tissue Bank
China Cord Blood Corp.
China Kadoorie Biobank
China Stem Cells
CIRM (California Institute of Regenerative Medicine)
CLB/Amsterdam Medical Center
Clinical Proteomic Tumor Analysis Consortium (CPTAC)
CMD Biobank
CONCOR
CorCell
Cord Blood Registry (CBR)
CordBlood America
CordLife
CordVida
CORE Informatics
Coriell Institute for Medical Research
Council of Europe (CoE)
Covance
Croydon NHS Trust
Cryo Bio System
Cryo Save
Cryo-Cell International
Cryogene Lab
CryoLogic
Cryopraxis
CryoXtract Instruments
Cureline
Custom Biogenic Systems
Cybrdi
Daifuku
Danubian Biobank Consortium
deCODE Genetics
Deloitte
Scottish Government
Eli Lilly
EMA
Eppendorf
Esco
Estonian Genome Center
European Association for Predictive, Preventative & Personalised Medicine (EPMA)
European Bank for induced pluripotent stem cells (EBiSC)
European Commission (EC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Health Risk Monitoring (EHRM)
European Research Infrastructure Consortium (ERIC)
European Union Group on Ethics (EGE)
FDA
Fisher BioServices
FluidX
Fox Chase Cancer Centre
Future Health Biobank
GC Biotech
GE Healthcare
GE Healthcare SeqWright Genomic Services
Genentech
GenVault
Germany Cryo
Gilson
GlaxoSmithKline
Golden Meditech Holdings
H. Lee Moffitt Cancer Center and Research Institute
Haier Biomedical
Hamilton
Hamilton Robotics
Hamilton Storage Technologies
Harvard Stem Cell Institute
Hitachi Chemical
Hospital Necker Paris
Hubris (HUNT Biobank Resource Information System)
Hudson Robotics
Human Genome Project
Human Longevity
Human Science Research Resource Bank (HSRRB)
Human Tissue Bank
Hungarian Biobank
HUNT Norway
Huntington Disease Biobank
ILSBio
Imperial Tissue Bank
Inbiomed
Indian Institute of Technology
Indivumed
Infectious Disease Biobank
INSERM
Instituto de Salud Carlos III (ISCIII)
IntegenX
International Agency for Research on Cancer (IARC)
International Organization for Standardization
International Society for Biological and Environmental Repositories (ISBER)
International Stem Cell Corporation
Japan Health Sciences Foundation
Kaiser Permanente
King's College London Tissue Bank
KORAgen
Kyoto University
Labtech
Labvantage Solutions
Labware
LBD Life Sciences
Leiden Longevity
Leiden University Medical Center
LifeBank USA
LifeCell
LifeGene
LifeLines Biobank
Malmo Microbiology Biobank
MatriCal Biosciences
Medical Research Council
Merck & Co.
Merck-Serono
Micronic
Minister of State for Public Health
Ministry of Health and Welfare
Mitochondrial Disease Biobank
MSD
Nanjing Xinjiekou Department Store Co.
Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center
National Cancer Institute (NCI)
National Health and Family Planning Commission (NHFPC)
National Institute of Standards and Technology (NIST)
National Institutes of Biomedical Innovation, Health and Nutrition (NIBHN)
National Institutes of General Medical Sciences (NIGMS)
National Institutes of Health (NIH)
NeoStem
NESDA
Netherlands Twin Registry
NHS Blood and Transplant Cord Blood Bank
NIGMS Human Genetic Cell Repository
Northwest Regional Development Agency
Novare Biologistics
Novartis
Ocimum Biosolutions
Office of Biorepositories and Biospecimen Research (OBBR)
OnCore UK
Organisation for Economic Co-operation and Development (OECD)
OriGene
P3G Consortium (Public Population Projects in Genomics)
Pacific BioStorage
PALGA
Panasonic Biomedical
Parelsnoer
PerkinElmer
Pfizer
Pharmacells
Pharmagene
Pop-Gen National Cohort
Precious Cells
Precision Bioservices
PrecisionMed
PREVEND
Progenicyte
Progenitor Cell Therapy (PCT)
ProMedDx
Promega
ProteoGenex
Provia Labs
Qiagen
RAND
ReproCELL Group
Riken BRC Cell Bank
Roche
Rotterdam Study
RTS Life Sciences
Russian Society of Personalised Medicine (RSPM)
Saneron CCEL Therapeutics
Sanofi
Sapien Biosciences
Sartorius Stedim Biotech
Sceil
Seattle Genetics
Sechenov First Moscow Medical University (SFMMU)
S-Evans Biosciences (SEB)
Singapore Biobank (SBB)
Singapore Cord Blood Bank
Singapore Tissue Network (STN)
Smart Cells
Spanish Ministry of Science and Innovation (MICINN)
Spanish National Biobank Network
Stanford Tissue Bank
Stanford University
StarLIMS
Steelgate
Stellacure
Stem Cells for Safer Medicine
Stemcyte
Stemgent
StemLife
StemSave
Swedish Institute for Infectious Disease Control Biobank
System Biosciences
Taiyo Nippon Sanso
TAP Biosystems
Tata Memorial Hospital Tissue Bank
TCG Life Sciences Tissue Bank
TCGA (The Cancer Genome Atlas Project)
Tecan
The Cambridge Brain Bank
The Centre for Integrated Genomic Medical Research
The Guangzhou Biobank
The National Cancer Tissue Bank
Thermo Genesis
Thermo Scientific
Tissue Solutions
Titan Pharmaceuticals
Totipotent
TRT (Tissue Regeneration Therapeutics)
TTP Labtech
UCL Biobank
UK Biobank
UK Blood Service Collection
UK ME-CFS Biobank
UK Multiple Sclerosis Tissue Bank
UK Parkinson's Disease Tissue Bank
UK Stem Cell Bank
UK Stem Cell Strategic Forum
University of South Florida
University of Tüebingen
US Biomax
US Department of Transportation's (DOT's)
V.A. Almazov Federal Center for Heart, Blood and Endocrinology
ViaCell
ViaCord
VidaPlus
Virgin Health Bank
Wellcome Trust
Wellcome Trust Case-Control Consortium (WTCCC)
Wheaton
Wisconsin International Stem Cell (WISC) Bank
World Health Organization (WHO)
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Share this article